IQVIA Holdings (IQV) AI Stock Analysis

IQVIA Holdings

(BMV:IQV)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Steady Growth and ProfitabilityIQVIA has expanded revenue while sustaining healthy operating and net margins, indicating a resilient service model and effective cost control. This combination supports recurring investment in technology and delivery capabilities, giving the company a durable base for continued growth across the product lifecycle.

Negative Factors

Elevated LeverageHigh leverage reduces financial flexibility and leaves earnings and cash flow more exposed to refinancing conditions and interest costs. Although IQVIA generates substantial cash, debt service and maturity management can constrain acquisitions, technology investment, and the company’s ability to absorb weaker demand.

IQVIA Holdings (IQV) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 44.06B
Dividend Yield: ―
Average Volume (3M): 1,030
Price to Earnings (P/E): 32.1
Beta (1Y): 0.00
Revenue Growth: -2.31%
EPS Growth: 2.03%
Country: Mexico
Employees: 94,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

IQVIA Holdings Business Overview & Revenue Model

Company Description

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-P...

IQVIA Holdings Earnings Call Summary

Earnings Call Date:Oct 26, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 10, 2027

Earnings Call SentimentPositive

The call was strongly positive. IQVIA reported revenue, adjusted EBITDA, and adjusted EPS above guidance; accelerating organic growth across clinical and commercial solutions; record four-year clinical bookings; improving win rates; strong demand indicators; expanding AI adoption; strong free cash flow; and raised full-year guidance. The principal challenges were the $2.1 billion inactive-trial backlog adjustment, pass-through and foreign-exchange headwinds, difficult fourth-quarter comparisons, leverage, and historical market uncertainty, but management explicitly stated that the backlog adjustment did not affect financial results or guidance and emphasized continued operational momentum.

Positive Updates

Revenue Exceeded Guidance with Accelerating Organic Growth

Third-quarter revenue was $4.43 billion, up 8% on a reported basis and 8.6% at constant currency. Organic revenue growth was approximately 6%, more than 2x the rate delivered a year ago. Revenue exceeded the high end of guidance.

Negative Updates

Backlog Adjustment for Inactive Trials

A detailed review of inactive trials resulted in an approximately $2.1 billion adjustment to backlog. The trials had generally been inactive for more than 18 months and, in coordination with customers, there was no reason to assume the work would resume in the near term. Management stated that this adjustment had no impact on historical financial results, 2026 guidance, net new bookings, or next-12-month revenue from backlog.

Company Guidance

Management raised full year 2026 guidance, expecting revenue to be between 17.350 billion and $17.5 billion, representing year over year growth of 6.4% to 7.3%, with >1 point constant currency or revenue growth acceleration versus prior year, approximately 200 to 250 basis points of contribution from acquisitions, and approximately 20 basis points of tailwind from foreign exchange; adjusted EBITDA is expected to be between 4.025 billion and $4.055 billion, growing 6.3 to 7% year over year with flat margins year over year at approximately 23.2%; adjusted diluted EPS is expected to be between $12.90 and $13, up 8.2 to 9.1% versus prior year or 8.6% at the midpoint; fourth-quarter run rate assumptions include net interest expense around $210 million, just over $160 million in depreciation and amortization, and a weighted average diluted share count of approximately 169 million shares, with foreign currency rates as of October 26th continuing for the balance.

IQVIA Holdings Risk Analysis

IQVIA Holdings disclosed 51 risk factors in its most recent earnings report. IQVIA Holdings reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

IQVIA Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:IQV against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDP	84Outperform	$18.24B	35.51	99.76%	―	20.35%	25.24%
DGX	76Outperform	$27.71B	24.74	15.21%	1.34%	9.13%	17.93%
LH	75Outperform	$29.31B	29.45	11.54%	0.80%	6.02%	19.63%
ICLR	69Neutral	$16.31B	36.13	4.85%	―	0.67%	43.70%
CRL	58Neutral	$17.16B	-74.26	-7.72%	―	-0.74%	-268.79%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:IQV and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:IQV	IQVIA Holdings	5213.94	1548.11	42.23%
CRL	Charles River Laboratories Intl	359.41	180.55	100.94%
ICLR	Icon Plc	211.36	42.57	25.22%
LH	Labcorp Holdings Inc.	361.39	106.13	41.58%
DGX	Quest Diagnostics	251.82	75.94	43.18%
MEDP	Medpace Holdings Inc	652.01	57.99	9.76%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

IQVIA Holdings AI Stock Analysis